COPD患者中不同ICS/LABA组合的安全性与有效性比较
本研究基于台湾2009至2015年国家健康保险理赔数据,纳入新使用ICS/LABA的COPD患者,采用倾向评分匹配和Cox回归比较不同组合的严重肺炎与急性加重风险。结果显示,与丙酸氟替卡松/沙美特罗相比,布地奈德/福莫特罗和倍氯米松/福莫特罗的严重肺炎及严重急性加重风险均更低。
要点
- 与FLU/SAL相比,BUD/FOR和BEC/FOR的严重肺炎风险显著更低。
- 与FLU/SAL相比,BUD/FOR和BEC/FOR的严重急性加重风险显著更低。
- 额外调整每日ICS平均剂量后,仅BUD/FOR干粉吸入器的严重肺炎风险仍显著降低18%。
核心结论
- 在COPD患者中,BUD/FOR干粉吸入器和BEC/FOR定量吸入器相比同装置类型的FLU/SAL,与更低的严重肺炎和严重急性加重风险相关。
研究设计与样本
- 回顾性队列研究,使用台湾2009至2015年国家健康保险理赔数据,纳入新使用ICS/LABA的COPD患者,采用倾向评分匹配和Cox回归模型估计风险比。
主要发现
- 与FLU/SAL相比,BUD/FOR的严重肺炎HR为0.83(95%CI 0.70-0.98),BEC/FOR的HR为0.69(95%CI 0.58-0.81)。
- 与FLU/SAL相比,BUD/FOR的严重急性加重HR为0.88(95%CI 0.78-0.99),BEC/FOR的HR为0.82(95%CI 0.72-0.93)。
- 额外调整每日ICS平均剂量后,BUD/FOR干粉吸入器用户的严重肺炎风险仍显著降低18%,而BEC/FOR定量吸入器用户则未显示显著降低。
- 结果在多数预设亚组和所有敏感性分析中一致。
临床怎么用
- 临床决策选择COPD患者的ICS/LABA组合时,可考虑不同组合在严重肺炎和急性加重风险上的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The differential risk of pneumonia among inhaled corticosteroid (ICS) use in patients with COPD requires more investigation, especially regarding beclomethasone-containing inhalers. The goal of this study was to compare the risk and benefit profile of different ICS/long-acting β2-agonist (LABA) combinations in patients with COPD. METHODS: This retrospective cohort study was conducted by using national health insurance claims data from the years 2009 to 2015 in Taiwan and included patients with COPD with new ICS/LABA use. Propensity score matching and Cox regression models were used to estimate the hazard ratios of severe pneumonia and acute exacerbation for different ICS/LABA users. RESULTS: Both budesonide/formoterol (BUD/FOR) dry-powder inhalers and beclomethasone/formoterol (BEC/FOR) metered-dose inhalers, compared with fluticasone propionate/salmeterol (FLU/SAL) delivered via the same device type, were associated with a lower risk of severe pneumonia (BUD/FOR hazard ratio [HR], 0.83 [95% CI, 0.70-0.98]; BEC/FOR HR, 0.69 [95% CI, 0.58-0.81]) and severe acute exacerbation (BUD/FOR HR, 0.88 [95% CI, 0.78-0.99]; BEC/FOR HR, 0.82 [95% CI, 0.72-0.93]). After additionally adjusting for the average daily ICS dose, BUD/FOR dry-powder inhaler users continued to have a significantly decreased risk of severe pneumonia (18%), although BEC/FOR metered-dose inhaler users did not. The results were consistent in most of the prespecified subgroups and across all the sensitivity analyses. CONCLUSIONS: This study augments the existing evidence concerning the different safety and effectiveness outcomes of ICS/LABA combinations in patients with COPD, which may be considered when making clinical treatment decisions.
引用
- Chang TY, Chien JY, Wu CH, et al. Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β2-Agonist Combinations in Patients With COPD. Chest. 2019. PMID: 31887282. doi:10.1016/j.chest.2019.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。